Stock Ratings / Health Care / SEER / forecast

QTRX (28) LAB (41) HBIO (44) RPID (47) ⌘ Pro Terminal →

Seer Inc. (Class A) (SEER) 12-Month Stock Forecast & Price Target Cone

Q: Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.94 (-2.51% 1D, market cap $107.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SEER ranks #945 in composite RQD confidence.

Q: How does SEER compare to QTRX and LAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $148.7M) and LAB (Standard BioTools Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for SEER?

Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is SEER trading relative to its 50-day, 200-day, and 52-week technical levels?

SEER last traded at $1.94 (-2.51% on volume of 177,567 shares), positioning the stock -3.48% below its 50-day simple moving average ($2.01) and +1.04% above its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 47.0% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±11.3% ($1.72 to $2.16).

Q: What is SEER's 12-month stock price target?

Seer Inc. (Class A) (SEER) carries a 12-month consensus base price target of $1.7 (-12.4% from $1.94), with a bull-case target of $2.5 and a bear-case floor of $1.33.

Q: Is SEER stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SEER E (Strong Sell — SELL) with an RQD Confidence score of 30/100.

$1.94 -2.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.93

Seer Inc. (Class A) (SEER) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $107.4M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $1.93 (-0.64%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SEER)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (30/100 Composite)

🔍 WHY SEER SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (27% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (27% of score)

FRED Regime × Technicals: 47% of 52W Range • RSI-14 at 27.4 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$2.19-7.3% Next Q

Q2 (-2Q)

Grade E$2.03-3% Next Q

Q3 (-1Q)

Grade E$1.97-1.5% Next Q

Current

Grade E$1.94-9.6% Hist 90D α

Trajectory: E (38) → E (30)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SEER Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SEER currently carries a cautious 30/100 (E) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.01) and Max Pain ($2.04) forces dealer call-delta covering toward $2.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SEER• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SEER Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 30%NO 70%Trade / Inspect Odds →

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your SEER Position Size: $10,000

Shares at $1.94: 5154.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $1.33

$6,856

$-3,144 (-31.4%)

12M Consensus BaseTarget $1.70

$8,763

$-1,237 (-12.4%)

12M Bull Case BreakoutTarget $2.50

$12,887

+$2,887 (+28.9%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 17● Hold: 9● Sell: 9

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	HOLD	$2	74%	A
Goldman SachsSector Coverage Lead	UNDERPERFORM	$2	69%	B
JP MorganUS Large-Cap Research	SELL	$2	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SEER)

✓Walkthrough of SEER's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SEER // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -0.51%📐 HORIZONTAL RANGE

2026-10-30O $1.89H $1.94L $1.62C $1.94VOL 516.5K

RES: $2.43SUP: $1.76SMA50: $2.01SMA200: $1.92

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SEER Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SEER Butterfly Map → + Track SEER →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +17.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SEER today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SEER. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SEER today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SEER)

Health Care Rank #945 of 1016 ⚔️ QTRX vs SEER Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SEER vs. QTRX, LAB, HBIO, RPID)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Seer Inc. (Class A) (SEER) ranks #945 by composite RQD confidence (30/100, grade E) and #649 by equity capitalization ($107.4M). Within this direct 5-issuer industry benchmark cohort, SEER leads on earnings valuation at N/A trailing P/E, while LAB leads on capital efficiency and profitability with -28.7% ROIC and 49.9% gross margin. RPID currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with SEER at 30/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SEER ACTIVE Seer Inc. (Class A)	E	30/100	—	51.1%	-29.1%	-2.51%	$107.4M	Benchmark Subject
QTRX Quanterix Corporation	E	28/100	—	46.8%	-35.0%	+0.80%	$148.7M	/qtrx-vs-seer →
LAB Standard BioTools Inc.	D-	41/100	—	49.9%	-28.7%	+0.49%	$244.7M	/lab-vs-seer →
HBIO Harvard Bioscience Inc.	D	44/100	—	57.7%	-35.0%	+4.51%	$40.1M	/hbio-vs-seer →
RPID Rapid Micro Biosystems Inc. (Class A)	D	47/100	—	—	-35.0%	-1.37%	$39.6M	/rpid-vs-seer →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001726445

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Seer Inc. (Class A) (SEER) reported GAAP revenue of $16.6M (+17.0% vs. FY2024 revenue of $14.2M , and -0.5% cumulative change since FY2023) , GAAP net income of -$73.6M, operating cash flow of -$44.4M, and free cash flow of -$46.2M (+6.9% YoY). On the balance sheet, SEER closed FY2025 with $296.1M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$16.6M	-$73.6M	-$44.4M	-$46.2M	$296.1M	—
FY2024 (FY)	2024-12-31	$14.2M	-$86.6M	-$46.1M	-$49.7M	$366.6M	—
FY2023 (FY)	2023-12-31	$16.7M	-$86.3M	-$59.1M	-$59.1M	—	—

3. SEER Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SEER stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Seer Inc. (Class A) (NASDAQ: SEER) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $1.94 (-2.51% 1D, market cap $107.4M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SEER ranks #945 in composite RQD confidence.

How does SEER compare to QTRX and LAB in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), SEER carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of 51.1%, and ROIC of -29.1%. By comparison, QTRX (Quanterix Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $148.7M) and LAB (Standard BioTools Inc.) posts a D- grade (41/100 RQD, P/E N/A, ROIC -28.7%, cap $244.7M). Among the 5-stock peer group, SEER leads on earnings multiple (N/A) while LAB leads on capital efficiency (-28.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SEER?

Per SEER's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001726445), Seer Inc. (Class A) generated $16.6M in revenue (+17.0% YoY), -$73.6M in net income, and -$46.2M in free cash flow against $296.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SEER trading relative to its 50-day, 200-day, and 52-week technical levels?

SEER last traded at $1.94 (-2.51% on volume of 177,567 shares), positioning the stock -3.48% below its 50-day simple moving average ($2.01) and +1.04% above its 200-day simple moving average ($1.92). Across its 52-week range of $1.55 to $2.38, SEER sits at the 47.0% percentile with a 14-day RSI of 27.4 (OVERSOLD (<32)) and an implied next-earnings move of ±11.3% ($1.72 to $2.16).

SEER Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is SEER's 12-month stock price target?

Seer Inc. (Class A) (SEER) carries a 12-month consensus base price target of $1.7 (-12.4% from $1.94), with a bull-case target of $2.5 and a bear-case floor of $1.33.

Is SEER stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates SEER E (Strong Sell — SELL) with an RQD Confidence score of 30/100.

Direct Sub-Reports: SEER RQD Cockpit SEER 12M Forecast SEER Earnings & Move SEER Dividends & DRIP SEER Insiders & 13F SEER Whale Options SEER Profit Sankey SEER News & Why